Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

European drug regulator accepts Mylan-Biocon application for biosimilar Pegfilgrastim

The proposed biosimilar Pegfilgrastim, used to treat cancer, is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace

BS B2B Bureau  |  Bangalore 

The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) of Biocon and Mylan for their biosimilar Pegfilgrastim, which is prescribed for cancer patients to help them with some of the side-effects of their treatment. It reduces the duration of neutropenia (low levels of neutrophils, a type of white blood cell that fights infections) and the incidence of febrile neutropenia (neutropenia with fever) that are a result of their chemotherapy treatment. Mylan and Biocon, who have co-developed the proposed biosimilar, received EMA's acceptance of ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
First Published: Fri, July 22 2016. 12:25 IST
RECOMMENDED FOR YOU

European drug regulator accepts Mylan-Biocon application for biosimilar Pegfilgrastim

The proposed biosimilar Pegfilgrastim, used to treat cancer, is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace

The proposed biosimilar Pegfilgrastim, used to treat cancer, is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) of Biocon and Mylan for their biosimilar Pegfilgrastim, which is prescribed for cancer patients to help them with some of the side-effects of their treatment. It reduces the duration of neutropenia (low levels of neutrophils, a type of white blood cell that fights infections) and the incidence of febrile neutropenia (neutropenia with fever) that are a result of their chemotherapy treatment. Mylan and Biocon, who have co-developed the proposed biosimilar, received EMA's acceptance of ... image
Business Standard
177 22

European drug regulator accepts Mylan-Biocon application for biosimilar Pegfilgrastim

The proposed biosimilar Pegfilgrastim, used to treat cancer, is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace

The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) of Biocon and Mylan for their biosimilar Pegfilgrastim, which is prescribed for cancer patients to help them with some of the side-effects of their treatment. It reduces the duration of neutropenia (low levels of neutrophils, a type of white blood cell that fights infections) and the incidence of febrile neutropenia (neutropenia with fever) that are a result of their chemotherapy treatment. Mylan and Biocon, who have co-developed the proposed biosimilar, received EMA's acceptance of ...

image
Business Standard
177 22